Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyoscine Butylbromide for Bradycardia Prevention in Cesarean Section
NCT04069078Phase 4Completed
- Sponsor
- Assiut University
- Start
- Oct 2019
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, triple-blind trial of hyoscine butylbromide in bradycardia (2 arms), sponsored by Assiut University. Primary endpoint: Incidence of Bradycardia. Started Oct 2019; status: completed.
02
Drugs
hyoscine butylbromide
03
Conditions
bradycardia
Beyond the preview
Go deeper on NCT04069078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04069078.